AmerisourceBergen unveils hub to aid cell and gene therapy data exchange
26 Apr 2023
Gene TherapyClinical Study
Preview
Source: FierceBiotech
Physicians and patient services teams will be able to get a clearer view of novel therapy development and the delivery process with AmerisourceBergen's Cell and Gene Therapy Integration Hub.
AmerisourceBergen released its platform focused on cell and gene therapies to speed the exchange of real-time data with the goal of aiding development and ultimately getting novel treatments to patients.
Dubbed the Cell and Gene Therapy (CGT) Integration Hub, the platform gives physicians and patient services teams enhanced visibility across the therapy development and delivery process. It works in conjunction with AmerisourceBergen’s customer relationship management system, the company said in an April 24 press release.
The hub was designed to speed the benefits investigation process, give a real-time view of therapy development and transportation status to help coordinate patient scheduling, and deliver status changes such as delayed arrival dates so case managers can contact patients or caregivers to make appropriate adjustments.
With the hub, the company can complete platform integrations with various supply chain partners, including therapy developers and CGT software providers.
“We are on the verge of several landmark CGT approvals this year in the United States, which reflects the rapid pace at which this sector is moving,” Lung-I Cheng, AmerisourceBergen’s vice president of CGT, said in the release. “Our role in the pharmaceutical supply chain, coupled with our commercialization expertise, enables us to play a vital role in helping to advance innovation and access to these products.”
With the hub, the global healthcare company can accomplish platform integrations with supply chain partners, including therapy developers and CGT software providers. To that end, AmerisourceBergen recently completed a platform integration with TrakCel’s cell orchestration platform OCELLOS.
Last May, the company released its Clinical Trial Navigator that supports recruitment for biopharmaceutical companies’ clinical trials. It was designed to connect biopharma companies with independent oncology practice groups across the country.
AmerisourceBergen is set to rebrand itself as Cencora the second half of this year.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.